8-K: Kronos Bio Provides Update on Clinical Programs and Reports 2023 Financial Results

Kronos Bio announced progress in its clinical programs, including the advancement of KB-0742 and KB-9558, and reported its fourth-quarter and full-year 2023 financial results.

Summary

• Kronos Bio reported its fourth-quarter and full-year 2023 financial results, highlighting progress in its clinical programs.
• The Phase 1/2 study of KB-0742 is on track to clear the 80mg four-days-on, three-days-off schedule in the third quarter of 2024, with topline data from the expansion cohort expected in the first half of 2025.
• IND-enabling studies for KB-9558 are expected to be completed in 2024, with a first-in-human study anticipated to commence in the first half of 2025.
• The company had $175.0 million in cash, cash equivalents, and investments as of December 31, 2023, providing an expected cash runway into the second half of 2026.
• Research and development expenses were $18.7 million for the fourth quarter of 2023 and $86.4 million for the full year.
• General and administrative expenses were $10.9 million for the fourth quarter of 2023 and $41.7 million for the full year.
• The net loss for the fourth quarter of 2023 was $25.3 million, or $0.43 per share, and the net loss for the full year was $112.7 million, or $1.95 per share.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical programs and a sufficient cash runway, but also acknowledges the financial losses and the discontinuation of one program. The sentiment is cautiously optimistic.

Positives

• KB-0742 has demonstrated a differentiated safety profile compared to other CDK9 inhibitors.
• The extended dosing schedule of KB-0742 is expected to show increased efficacy while maintaining a favorable safety profile.
• KB-9558, a p300 KAT inhibitor, has been nominated as a development candidate.
• The company has extended its cash runway into the second half of 2026 through restructurings and resource optimization.
• The company is making progress on multiple clinical programs.

Negatives

• The company experienced a net loss of $25.3 million in the fourth quarter of 2023 and $112.7 million for the full year.
• The company decided not to proceed to Phase 2 with lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory AML.

Risks

• There are risks associated with changes to the assumptions underlying estimated expenses and savings.
• Changes in the macroeconomic environment or competitive landscape could impact Kronos Bio's business.
• There are risks inherent in the clinical development of novel therapeutics, which could affect the timelines of clinical trials.
• The company has limited experience in conducting clinical trials.
• Results of preclinical studies and early clinical trials may not be predictive of future results.
• There are risks associated with the sufficiency of Kronos Bio's cash resources and the need for additional capital.

Future Outlook

The company anticipates sufficient resources to fund its planned operations into the second half of 2026 and expects to achieve key milestones in its clinical programs, including the completion of IND-enabling studies for KB-9558 and the release of topline data for KB-0742.

Management Comments

• We demonstrated that KB-0742 has a safety profile that is clearly differentiated from all other CDK9 inhibitors, and we believe our extended dosing schedule will show increased efficacy signals while maintaining a favorable safety profile, said Nobert Bischofberger, Ph.D., president and chief executive officer of Kronos Bio.
• We also announced our second development candidate, KB-9558, which is designed to target the KAT domain of p300 and downregulate IRF4 transcription in multiple myeloma.
• We are looking forward to completing the IND-enabling studies in 2024 and expect to dose our first patients in the first half of 2025.

Industry Context

This announcement reflects the ongoing efforts in the biopharmaceutical industry to develop novel cancer therapies, particularly those targeting deregulated transcription. The focus on CDK9 and p300 inhibitors aligns with current research trends in oncology.

Comparison to Industry Standards

• The development of KB-0742 as a CDK9 inhibitor is comparable to other companies working in this space, such as Syros Pharmaceuticals with their CDK7 inhibitor, tamibarotene, which has shown some efficacy in AML and MDS.
• The focus on p300 KAT inhibition with KB-9558 is similar to efforts by companies like Constellation Pharmaceuticals (now part of MorphoSys) who have explored BET inhibitors, which also target transcriptional regulation, though with a different mechanism.
• The reported cash runway into the second half of 2026 is a positive sign, as many biotech companies face funding challenges, and this provides a longer period for clinical development without immediate capital concerns. This is comparable to companies like Relay Therapeutics who have also secured funding to support their clinical programs.
• The decision to not proceed with lanraplenib is not uncommon in the industry, as companies often need to make tough choices based on clinical data. This is similar to decisions made by companies like Agios Pharmaceuticals who have discontinued programs based on efficacy or safety data.

Stakeholder Impact

• Shareholders may view the progress in clinical programs and extended cash runway positively.
• Employees may be encouraged by the company's continued development and financial stability.
• Patients may benefit from the potential development of new cancer therapies.
• Creditors may be reassured by the company's financial position.

Next Steps

• The company will continue the Phase 1/2 study of KB-0742, aiming to clear the 80mg four-days-on, three-days-off schedule in Q3 2024.
• Topline data from the KB-0742 expansion cohort is expected in the first half of 2025.
• IND-enabling studies for KB-9558 are expected to complete in 2024, with a first-in-human study anticipated in the first half of 2025.
• The company plans to present data on KB-9558 at the AACR annual meeting in April 2024.

Key Dates

Keywords

KB-0742, KB-9558, clinical trials, cancer, CDK9 inhibitor, p300 KAT inhibitor, multiple myeloma, financial results, research and development, biopharmaceutical